Please assess the completion status of the following clinical trial:

Trial Title: Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of:~  * Acute myeloid or lymphoid leukemia in remission,~ * Myelodysplastic syndrome,~ * Chronic lymphoid leukemia,~ * Non-Hodgkin lymphoma,~ * Hodgkin lymphoma,~ * Chronic myeloid leukemia in chronic or accelerated phase,~ * Myeloproliferative disorder, or~ * Multiple myeloma~* Undergoing allogeneic HSC transplantation from a related or unrelated donor matched at least at 7 of 8 of the HLA-A, -B, -C, and DR loci (8/8 or 7/8 match)~* Undergoing allogeneic HSC transplantation after a myeloablative TBI-, busulfan-, or (non-myeloablative) melphalan-based pre-transplant conditioning regimen. Regimens for transplantation will include at one of the following agents, given in conjunction with fludarabine or cyclophosphamide:~  * Busulfan 130 mg/m2 iv daily x 2 (reduced intensity) or 4 days~ * TBI 150 cGy bid x8 doses (1200 Gy)~ * Melphalan 140 mg/m2. (Although melphalan is not a myeloablative regimen, it results in clinically significant mucositis and patients receiving this medication will be of considerable interest in the analysis of these data.)~* Male or female patient age 18 years or older~* Karnofsky performance status \> 70% at time of initiation of pre-transplant conditioning~* Transplantation-specific co-morbidity score of \<5 at time of initiation of pre-transplant conditioning~* Patients taking antihypertensive medications (including telmisartan) are eligible but the patient must discontinue treatment at least 48 hours prior to first dose of study medication~* Capable of giving informed consent and having signed the informed consent form~Exclusion Criteria:~* Inability to provide informed consent~* Subjects with known heart failure, advanced renal impairment requiring renal replacement therapy, or liver failure although these patients would most likely not be eligible for HCT.~* Subjects taking ACE inhibitors, potassium supplements, or spironolactone (or any other potassium-sparing diuretics) who cannot discontinue use prior to initiation of study treatment OR who require a high-potassium diet~* Patient unable to discontinue current hypertension medication for medical or other reasons for two days prior to starting telmisartan~* Chronic symptomatic hypotension, volume depletion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 160 mg Telmisartan (Type: EXPERIMENTAL): 60 patients will receive 160 of Telmisartan (2 80 mg tablets) for 101 days

Based on this trial design, predict the completion outcome and termination type (if applicable).